Literature DB >> 29636328

Should all patients with HL who relapse after ASCT be considered for allogeneic SCT? A consult, yes; a transplant, not necessarily.

Craig H Moskowitz1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2018        PMID： 29636328      PMCID： PMC5894256          DOI： 10.1182/bloodadvances.2017011130

Source DB:  PubMed          Journal:  Blood Adv        ISSN： 2473-9529


× No keyword cloud information.
  29 in total

1.  Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed/Refractory Classic Hodgkin Lymphoma.

Authors:  Robert Chen; Pier Luigi Zinzani; Michelle A Fanale; Philippe Armand; Nathalie A Johnson; Pauline Brice; John Radford; Vincent Ribrag; Daniel Molin; Theodoros P Vassilakopoulos; Akihiro Tomita; Bastian von Tresckow; Margaret A Shipp; Yinghua Zhang; Alejandro D Ricart; Arun Balakumaran; Craig H Moskowitz
Journal:  J Clin Oncol       Date:  2017-04-25       Impact factor: 44.544

Review 2.  Relapse of Hodgkin lymphoma after autologous transplantation: Time to rethink treatment?

Authors:  Yogesh Jethava; Guru Subramanian Guru Murthy; Mehdi Hamadani
Journal:  Hematol Oncol Stem Cell Ther       Date:  2017-02-01

3.  Brentuximab vedotin as consolidation therapy after autologous stem-cell transplantation in patients with Hodgkin's lymphoma at risk of relapse or progression (AETHERA): a randomised, double-blind, placebo-controlled, phase 3 trial.

Authors:  Craig H Moskowitz; Auayporn Nademanee; Tamas Masszi; Edward Agura; Jerzy Holowiecki; Muneer H Abidi; Andy I Chen; Patrick Stiff; Alessandro M Gianni; Angelo Carella; Dzhelil Osmanov; Veronika Bachanova; John Sweetenham; Anna Sureda; Dirk Huebner; Eric L Sievers; Andy Chi; Emily K Larsen; Naomi N Hunder; Jan Walewski
Journal:  Lancet       Date:  2015-03-19       Impact factor: 79.321

Review 4.  PD-1-PD-L1 immune-checkpoint blockade in B-cell lymphomas.

Authors:  Aaron Goodman; Sandip P Patel; Razelle Kurzrock
Journal:  Nat Rev Clin Oncol       Date:  2016-11-02       Impact factor: 66.675

5.  CTLA-4 and PD-1 receptors inhibit T-cell activation by distinct mechanisms.

Authors:  Richard V Parry; Jens M Chemnitz; Kenneth A Frauwirth; Anthony R Lanfranco; Inbal Braunstein; Sumire V Kobayashi; Peter S Linsley; Craig B Thompson; James L Riley
Journal:  Mol Cell Biol       Date:  2005-11       Impact factor: 4.272

6.  Allogeneic stem cell transplantation after reduced intensity conditioning in patients with relapsed or refractory Hodgkin's lymphoma. Results of the HDR-ALLO study - a prospective clinical trial by the Grupo Español de Linfomas/Trasplante de Médula Osea (GEL/TAMO) and the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation.

Authors:  Anna Sureda; Carme Canals; Reyes Arranz; Dolores Caballero; Josep Maria Ribera; Mats Brune; Jacob Passweg; Rodrigo Martino; David Valcárcel; Joan Besalduch; Rafael Duarte; Angel León; Maria Jesus Pascual; Ana García-Noblejas; Lucia López Corral; Bianca Xicoy; Jordi Sierra; Norbert Schmitz
Journal:  Haematologica       Date:  2011-10-11       Impact factor: 9.941

7.  Guidelines for the evaluation of immune therapy activity in solid tumors: immune-related response criteria.

Authors:  Jedd D Wolchok; Axel Hoos; Steven O'Day; Jeffrey S Weber; Omid Hamid; Celeste Lebbé; Michele Maio; Michael Binder; Oliver Bohnsack; Geoffrey Nichol; Rachel Humphrey; F Stephen Hodi
Journal:  Clin Cancer Res       Date:  2009-11-24       Impact factor: 12.531

8.  PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome.

Authors:  Margaretha G M Roemer; Ranjana H Advani; Azra H Ligon; Yasodha Natkunam; Robert A Redd; Heather Homer; Courtney F Connelly; Heather H Sun; Sarah E Daadi; Gordon J Freeman; Philippe Armand; Bjoern Chapuy; Daphne de Jong; Richard T Hoppe; Donna S Neuberg; Scott J Rodig; Margaret A Shipp
Journal:  J Clin Oncol       Date:  2016-04-11       Impact factor: 44.544

9.  Results of a trial of PET-directed therapy for early-stage Hodgkin's lymphoma.

Authors:  John Radford; Tim Illidge; Nicholas Counsell; Barry Hancock; Ruth Pettengell; Peter Johnson; Jennie Wimperis; Dominic Culligan; Bilyana Popova; Paul Smith; Andrew McMillan; Alison Brownell; Anton Kruger; Andrew Lister; Peter Hoskin; Michael O'Doherty; Sally Barrington
Journal:  N Engl J Med       Date:  2015-04-23       Impact factor: 91.245

10.  Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial.

Authors:  Anas Younes; Armando Santoro; Margaret Shipp; Pier Luigi Zinzani; John M Timmerman; Stephen Ansell; Philippe Armand; Michelle Fanale; Voravit Ratanatharathorn; John Kuruvilla; Jonathon B Cohen; Graham Collins; Kerry J Savage; Marek Trneny; Kazunobu Kato; Benedetto Farsaci; Susan M Parker; Scott Rodig; Margaretha G M Roemer; Azra H Ligon; Andreas Engert
Journal:  Lancet Oncol       Date:  2016-07-20       Impact factor: 41.316
View more
  3 in total

1.  Allogeneic transplantation using TLI-ATG conditioning for Hodgkin lymphoma after failure of autologous transplantation.

Authors:  Michael A Spinner; Ranjana H Advani; Richard T Hoppe; Robert Lowsky; Lori S Muffly
Journal:  Blood Adv       Date:  2018-07-10

Review 2.  Reappraising the Role of Allogeneic Hematopoietic Stem Cell Transplantation in Relapsed and Refractory Hodgkin's Lymphoma: Recent Advances and Outcomes.

Authors:  Taha Al-Juhaishi; Azra Borogovac; Sami Ibrahimi; Matthew Wieduwilt; Sairah Ahmed
Journal:  J Pers Med       Date:  2022-01-18

3.  Allogeneic Stem Cell Transplantation for Relapsed and Refractory Hodgkin Lymphoma: Real World Experience of a Single Center.

Authors:  A Kopińska; A Koclęga; A Wieczorkiewicz-Kabut; K Woźniczka; D Kata; M Włodarczyk; G Helbig
Journal:  Pathol Oncol Res       Date:  2021-07-27       Impact factor: 3.201
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.